Experienced biotech founders, management and KOLs
-
David Broecker
CEO
Experienced biotech executive with a track record of venture formation and fundraising. Former CEO of Alkermes and executive with Lilly. Multi-time founder including Zorion Medical and IBRI.
Background: MIT, Lilly, Alkermes, Indiana Biosciences Research Institute (IBRI)
-
Bittoo Kanwar, MD
CMO
Trained as a gastroenterologist with 15+ years working with both large pharma and emerging biotechs with successful IPOs as well as acquisitions and partnerships with leading I&I biopharmaceutical companies.
Background: UCSF, Gilead, Protagonist Therapeutics, Telavant
-
Mark Kelley, PhD
CSO
Over 30 years of experience in translational science including oncology, ophthalmology, IBD and drug discovery. Founder and CSO of Apexian Pharmaceuticals since 2008. Author on numerous publications for Ref-1.
Background: Indiana University School of Medicine, The Rockefeller University, LSU, Apexian Pharmaceuticals
-
Ari Landon, PhD, MBA
VP of Finance & Investment
Public and private biotechnology company leadership experience focusing on intersection of R&D and Business Development. Experience running one of the largest life science portfolios in the country. Well versed with capital markets, advisor to VCs and IBs. Executed deals with over two dozen strategic partners.
Background: Yale, NYU, Rafael Holdings, Indiana Biosciences Research Institute (IBRI)
-
Tim Tichenor, MBA
CFO
Over 30 years of executive leadership. Proven track record of capital raises, board leadership and successful exits to large pharma and private equity. Pfizer, Eli Lilly, Yamatake, Arlington Capital, AKKR, Searchlight Capital Partners and Genstar.
Background: University of Notre Dame, Pearl Street Venture Advisory, Apexian Pharmaceuticals
-
Chris Vlahos, PhD, FAHA
VP of Business Development
Over 35 years of experience in R&D and external innovation, including due diligence and business development across large and emerging biopharma. Track record of 15 executed deals in cardiometabolic, neuroscience and rare disease.
Background: University of Michigan, Lilly, Ipsen, Acadia
-
Daniela Oniciu, PhD
SVP Integrated Product Development & CMC
Over 25 years of experience across drug discovery and integrated drug development, including CMC, nonclinical and clinical operations, and regulatory strategy through NDA. Inventor of Esperion’s LDL drug NEXLETOL®. Developing APX3330 since 2020.
Background: Politehnica University of Bucharest, Pfizer, Esperion, Ocuphire Pharma, Gemphire Therapeutics
Interested in learning more?
Contact our team for investor, partnership and clinical inquiries, or explore our published science.